Sugi Predict

Sugi Predict / Compounds / SCHEMBL2015242

SCHEMBL2015242

SCHEMBL2015242

CC(=O)c1nc(Cl)c2ccccc2c1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 5/20 0.38
▸ FTO Q9C0B1 4/20 0.38
▸ BBOX1 O75936 3/20 0.38
▸ HSD11B1 P28845 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ CXCR2 P25025 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2014981 0.75 KMT2A (0.42) HSD11B1KDM4EADORA2AADORA1ALDH1A1
SCHEMBL30641377 0.74 KDM4E (0.45) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL26674524 0.74 KDM4E (0.45) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL2012992 0.73 MEN1 (0.41) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL17287531 0.73 ADORA2A (0.36) KDM4EADORA2AADORA1CXCR2ALDH1A1
SCHEMBL17836993 0.72 HSD11B1 (0.46) HSD11B1CXCR2ALDH1A1HPGD
SCHEMBL25620910 0.70 HSD11B1 (0.40) HSD11B1CXCR2ALDH1A1HPGDMEN1
SCHEMBL18584448 0.70 ALOX15 (0.51) HSD11B1ALDH1A1MEN1KMT2A
SCHEMBL18609652 0.70 HSD11B1 (0.39) HSD11B1KDM4EADORA2AADORA1CXCR2
SCHEMBL2015310 0.70 EGLN1 (0.59) EGLN1FTOBBOX1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 EGLN1 1920/4885FTO 3465/4885BBOX1 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.